- Home
- MQT vs NKTR Comparison
MQT vs NKTR Comparison
Compare MQT & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQT
- NKTR
- Stock Information
- Founded
- MQT 1992
- NKTR 1990
- Country
- MQT United States
- NKTR United States
- Employees
- MQT N/A
- NKTR N/A
- Industry
- MQT Investment Bankers/Brokers/Service
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- MQT Finance
- NKTR Health Care
- Exchange
- MQT Nasdaq
- NKTR Nasdaq
- Market Cap
- MQT 239.7M
- NKTR 238.7M
- IPO Year
- MQT N/A
- NKTR 1994
- Fundamental
- Price
- MQT $10.65
- NKTR $1.32
- Analyst Decision
- MQT
- NKTR Buy
- Analyst Count
- MQT 0
- NKTR 4
- Target Price
- MQT N/A
- NKTR $2.50
- AVG Volume (30 Days)
- MQT 52.5K
- NKTR 1.0M
- Earning Date
- MQT 01-01-0001
- NKTR 11-05-2024
- Dividend Yield
- MQT 4.60%
- NKTR N/A
- EPS Growth
- MQT N/A
- NKTR N/A
- EPS
- MQT N/A
- NKTR N/A
- Revenue
- MQT N/A
- NKTR $93,157,000.00
- Revenue This Year
- MQT N/A
- NKTR N/A
- Revenue Next Year
- MQT N/A
- NKTR N/A
- P/E Ratio
- MQT N/A
- NKTR N/A
- Revenue Growth
- MQT N/A
- NKTR 6.17
- 52 Week Low
- MQT $8.59
- NKTR $0.41
- 52 Week High
- MQT $10.67
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- MQT 42.00
- NKTR 56.07
- Support Level
- MQT $10.81
- NKTR $1.11
- Resistance Level
- MQT $11.00
- NKTR $1.39
- Average True Range (ATR)
- MQT 0.08
- NKTR 0.09
- MACD
- MQT -0.03
- NKTR 0.01
- Stochastic Oscillator
- MQT 0.00
- NKTR 75.00
About MQT Blackrock MuniYield Quality Fund II Inc.
BLACKROCK MUNIYIELD QUALITY FUND II, INC. is a closed-end fund. Its objective is to provide shareholders with as high a level of current income exempt from federal income taxes as is consistent with its investment policies and prudent investment management. It invests in various sectors such as Transportation, Utilities, Health, County/City/Special District/School District, Education, and Housing.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.